P081: Dual anti-HER-2 blockade with primary systemic therapy for HER-2 positive non-metastatic breast cancer can increase breast conservation rates: Benefit beyond survival

Introduction: Dual anti-HER-2-blockade (Pertuzumab and Trastuzumab) increased pathological complete response (pCR) in trials. These were approved for clinical use as primary systemic therapy (PST) along with chemotherapy in 2016. The impact of response to PST is yet to filter into practice to increase Breast Conserving Surgery (BCS). This study analyses efficacy of anti-HER-2-blocking agents (dual vs. single agent) and potential impact on surgical planning.